CONCORD, CA, October
26, 2004 – In conjunction with Cerus Corporation's (Nasdaq:
CERS) report of its third quarter financial results, a live webcast
will be made of its conference call with Claes Glassell, president
and CEO
and William J. Dawson, vice president, finance and CFO.
| What: | Cerus Corporation third quarter financial results, with
an update on progress and future outlook |
| When: | Tuesday, November 9, 2004 at 4:30 p.m. ET |
| Where: | http://www.cerus.com/pages/IR/wc.html |
| Contact: | Lainie Corten / Cerus Corporation, 925-288-6319 |
The conference call is protected by copyright. It cannot be recorded
or rebroadcast without Cerus' permission.
Cerus Corporation is developing novel technologies to provide safer and
more effective therapeutic options to patients in areas with substantial
unmet medical needs, particularly within the fields of cancer, infectious
disease and blood safety. The Concord, California-based company is combining
its proprietary vector technologies with public domain and proprietary
antigens to develop new therapies for cancer and infectious disease. Cerus
has two therapeutic cancer vaccine products in development using its Listeria
vector technology, one in collaboration with MedImmune, Inc. and the other
with Johns Hopkins University. Cerus is also collaborating with subsidiaries
of Baxter International Inc. on the INTERCEPT Blood System, which is designed
to enhance the safety of donated blood components by inactivating viruses,
bacteria and other pathogens. The INTERCEPT Blood System is based on the
company's Helinx technology for controlling biological replication.
The INTERCEPT Blood System for platelets is approved for use in the European
Union and Canada.
Helinx is a trademark of Cerus Corporation
Baxter and INTERCEPT are trademarks of Baxter International
Inc.
If you are unable to participate during the live webcast, the
call will be temporarily archived at http://www.cerus.com/pages/IR/wc.html.